Description
Sovilnesib (AMG 650) is a kinesin-like protein KIF18A inhibitor (WO2020132648). Sovilnesib can be used for the research of cancer.
Uses
Sovilnesib (AMG 650) is a potent, orally active kinesin-like protein KIF18A inhibitor with an IC50 value of 0.071 μM. Sovilnesib can be used for the research of cancer[1][2].
in vitro
Sovilnesib is a kinesin-like protein KIF18A inhibitor.
in vivo
Sovilnesib (AMG 650; 10-100 mg/kg; p.o. daily, for 45 d; female nude mice without thymus with OVCAR-3 xenografts) inhibits tumor growth, Lasting tumor regression and cure occurred in 50% of the animals, Sovilnesib has no apparent toxicity.
Clinical claims and research
Sovilnesib (AMG-650) is under development for the treatment of triple-negative breast cancer (TNBC), platinum-resistant high grade serous ovarian cancer, primary peritoneal cancer, fallopian tube cancer, serous endometrial cancer and other solid tumors with TP53 gene mutation (TP53MUT). The drug candidate is administered orally as tablet. It acts by targeting KIF18A.
References
[1] Payton MN, et, al. Kif18a inhibitors for treatment of neoplastic diseases. WO2021211549
[2] Tamayo NA, et, al. Kif18a inhibitors. WO2020132648.
